BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Fruzaqla / Elunate (Fruquintinib) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Fruzaqla / Elunate (Fruquintinib)\, from 
 ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07229872-2237@assetmemo.bio
DTSTAMP:20261121T004030Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Fruzaqla / Elunate (Fruquintinib): Phase 2 readout est. (NCT0722987
 2)
DESCRIPTION:Fruzaqla / Elunate (Fruquintinib)\, phase 2\, Colorectal Cancer
 .\nStudy: A Phase II Clinical Study of Aipalolitovorelizumab (QL1706) Comb
 ined With Fruquintinib in the Treatment of Immunodominant pMMR/MSS Metasta
 tic Colorectal Cancer That Has Failed Second-line or Above Treatment\nEsti
 mated primary completion: December 2026. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/fruquintinib#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07229872
URL:https://assetmemo.bio/drug/fruquintinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06115733-2237@assetmemo.bio
DTSTAMP:20261121T004030Z
DTSTART;VALUE=DATE:20261215
DTEND;VALUE=DATE:20261216
SUMMARY:Fruzaqla / Elunate (Fruquintinib): Phase na readout est. (NCT061157
 33)
DESCRIPTION:Fruzaqla / Elunate (Fruquintinib)\, phase na\, Colorectal Cance
 r.\nStudy: Study of Fuquinitinib Combined With Capecitabine First-line Mai
 ntenance in the Treatment of Metastatic Colorectal Cancer\nEstimated prima
 ry completion: 15 December 2026. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/fruquintinib#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT06115733
URL:https://assetmemo.bio/drug/fruquintinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05954429-2237@assetmemo.bio
DTSTAMP:20261121T004030Z
DTSTART;VALUE=DATE:20261228
DTEND;VALUE=DATE:20261229
SUMMARY:Fruzaqla / Elunate (Fruquintinib): Phase 2 readout est. (NCT0595442
 9)
DESCRIPTION:Fruzaqla / Elunate (Fruquintinib)\, phase 2\, Colorectal Cancer
 .\nStudy: A Study to Explore the Third-line Treatment of Fruquintinib Comb
 ined With Serplulimab in Advanced Non-liver-limited Metastatic Colorectal 
 Cancer: a Single-center\, Phase 2 Study\nEstimated primary completion: 28 
 December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/fruqui
 ntinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT05954429
URL:https://assetmemo.bio/drug/fruquintinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06356597-2237@assetmemo.bio
DTSTAMP:20261121T004030Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Fruzaqla / Elunate (Fruquintinib): Phase 2 readout est. (NCT0635659
 7)
DESCRIPTION:Fruzaqla / Elunate (Fruquintinib)\, phase 2\, Colorectal Cancer
 .\nStudy: Tislelizumab With Fruquintinib\, Metronidazole\, in Mismatch Rep
 air-proficient or Microsatellite Stability\, Advanced Colorectal Cancer: a
  Multicenter\, Single Arm\, Clinical Trial\nEstimated primary completion: 
 30 December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/fru
 quintinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT06356597
URL:https://assetmemo.bio/drug/fruquintinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05848739-2237@assetmemo.bio
DTSTAMP:20261121T004030Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Fruzaqla / Elunate (Fruquintinib): Phase 1 readout est. (NCT0584873
 9)
DESCRIPTION:Fruzaqla / Elunate (Fruquintinib)\, phase 1.\nStudy: A Phase 1-
 2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors
 \nEstimated primary completion: 31 December 2026. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/fruquintinib#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT05848739
URL:https://assetmemo.bio/drug/fruquintinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05867420-2237@assetmemo.bio
DTSTAMP:20261121T004030Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Fruzaqla / Elunate (Fruquintinib): Phase 1/2 readout est. (NCT05867
 420)
DESCRIPTION:Fruzaqla / Elunate (Fruquintinib)\, phase 1/2.\nStudy: A Study 
 of ASKG915 in Patients With Selected Advanced Solid Tumors.\nEstimated pri
 mary completion: 31 December 2026. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/fruquintinib#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT05867420
URL:https://assetmemo.bio/drug/fruquintinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05747716-2237@assetmemo.bio
DTSTAMP:20261121T004030Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Fruzaqla / Elunate (Fruquintinib): Phase 2 readout est. (NCT0574771
 6)
DESCRIPTION:Fruzaqla / Elunate (Fruquintinib)\, phase 2\, Colorectal Cancer
 .\nStudy: SBRT Combined With Fruquintinib Plus PD-1/CTLA-4 Antibody for Th
 ird-line Treatment in mCRC\nEstimated primary completion: 31 December 2026
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/fruquintinib#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT05747716
URL:https://assetmemo.bio/drug/fruquintinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07257653-2237@assetmemo.bio
DTSTAMP:20261121T004030Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Fruzaqla / Elunate (Fruquintinib): Phase 2 readout est. (NCT0725765
 3)
DESCRIPTION:Fruzaqla / Elunate (Fruquintinib)\, phase 2\, Colorectal Cancer
 .\nStudy: The Safety and Efficacy of Cetuximab Beta Plus Fruquintinib With
  or Without Immune Checkpoint Inhibitorrs in First-line Treatment of RAS/B
 RAF Wild Type Unresectable Metastatic Colorectal Cancer\nEstimated primary
  completion: 31 December 2026. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/fruquintinib#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07257653
URL:https://assetmemo.bio/drug/fruquintinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07011576-2237@assetmemo.bio
DTSTAMP:20261121T004030Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Fruzaqla / Elunate (Fruquintinib): Phase 2 readout est. (NCT0701157
 6)
DESCRIPTION:Fruzaqla / Elunate (Fruquintinib)\, phase 2\, Colorectal Cancer
 .\nStudy: A Study of Fruquintinib Plus FOLFIRI as Second-Line Treatment fo
 r Participants With Metastatic Colorectal Cancer (FRUITFUL)\nEstimated pri
 mary completion: January 2027. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/fruquintinib#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07011576
URL:https://assetmemo.bio/drug/fruquintinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07446465-2237@assetmemo.bio
DTSTAMP:20261121T004030Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Fruzaqla / Elunate (Fruquintinib): Phase 4 readout est. (NCT0744646
 5)
DESCRIPTION:Fruzaqla / Elunate (Fruquintinib)\, phase 4\, Colorectal Cancer
 .\nStudy: FOLFOX Chemotherapy Combined With Fruquintinib and Serplulimab a
 s First-Line Conversion Therapy for Initially Unresectable pMMR/MSS Colore
 ctal Cancer\nEstimated primary completion: 31 January 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/fruquintinib#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07446465
URL:https://assetmemo.bio/drug/fruquintinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07510932-2237@assetmemo.bio
DTSTAMP:20261121T004030Z
DTSTART;VALUE=DATE:20270301
DTEND;VALUE=DATE:20270302
SUMMARY:Fruzaqla / Elunate (Fruquintinib): Phase 2 readout est. (NCT0751093
 2)
DESCRIPTION:Fruzaqla / Elunate (Fruquintinib)\, phase 2\, Colorectal Cancer
 .\nStudy: Fruquintinib In Patients With Metastatic Colorectal Cancer Refra
 ctory to Standard Chemotherapies in South Korea Patients (FIRST-K)\nEstima
 ted primary completion: 1 March 2027. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/fruquintinib#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT07510932
URL:https://assetmemo.bio/drug/fruquintinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06255379-2237@assetmemo.bio
DTSTAMP:20261121T004030Z
DTSTART;VALUE=DATE:20270321
DTEND;VALUE=DATE:20270322
SUMMARY:Fruzaqla / Elunate (Fruquintinib): Phase 2 readout est. (NCT0625537
 9)
DESCRIPTION:Fruzaqla / Elunate (Fruquintinib)\, phase 2\, Colorectal Cancer
 .\nStudy: Study of Fruquintinib Combined With Tegafur Gimeracil Oteracil i
 n Patients With Metastatic Colorectal Cancer\nEstimated primary completion
 : 21 March 2027. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/fruq
 uintinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT06255379
URL:https://assetmemo.bio/drug/fruquintinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07658872-2237@assetmemo.bio
DTSTAMP:20261121T004030Z
DTSTART;VALUE=DATE:20270519
DTEND;VALUE=DATE:20270520
SUMMARY:Fruzaqla / Elunate (Fruquintinib): Phase 2 readout est. (NCT0765887
 2)
DESCRIPTION:Fruzaqla / Elunate (Fruquintinib)\, phase 2.\nStudy: Perioperat
 ive Fruquintinib Combined With Sintilimab and SOX for Locally Advanced Gas
 tric or GEJ Adenocarcinoma\nEstimated primary completion: 19 May 2027. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/fruquintinib#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT07658872
URL:https://assetmemo.bio/drug/fruquintinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07920224-2237@assetmemo.bio
DTSTAMP:20261121T004030Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:Fruzaqla / Elunate (Fruquintinib): Phase 2 readout est. (NCT0792022
 4)
DESCRIPTION:Fruzaqla / Elunate (Fruquintinib)\, phase 2.\nStudy: Candonilim
 ab Combined With Fruquintinib and Paclitaxel Albumin-Bound as Second-Line 
 Treatment for Advanced Gastric or Gastro-esophageal Junction Adenocarcinom
 a\nEstimated primary completion: 1 June 2027. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/fruquintinib#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07920224
URL:https://assetmemo.bio/drug/fruquintinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05405595-2237@assetmemo.bio
DTSTAMP:20261121T004030Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Fruzaqla / Elunate (Fruquintinib): Phase 1/2 readout est. (NCT05405
 595)
DESCRIPTION:Fruzaqla / Elunate (Fruquintinib)\, phase 1/2.\nStudy: ADG126 i
 n Combination With Pembrolizumab in Patients With Advanced/Metastatic Soli
 d Tumors\nEstimated primary completion: 30 June 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/fruquintinib#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT05405595
URL:https://assetmemo.bio/drug/fruquintinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06973421-2237@assetmemo.bio
DTSTAMP:20261121T004030Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Fruzaqla / Elunate (Fruquintinib): Phase 2 readout est. (NCT0697342
 1)
DESCRIPTION:Fruzaqla / Elunate (Fruquintinib)\, phase 2.\nStudy: Phase II S
 tudy of Utidelone Plus Fruquintinib Combination Therapy for Platinum-Resis
 tant Recurrent Ovarian Cancer\nEstimated primary completion: 30 June 2027.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/fruquintinib#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT06973421
URL:https://assetmemo.bio/drug/fruquintinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07591597-2237@assetmemo.bio
DTSTAMP:20261121T004030Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Fruzaqla / Elunate (Fruquintinib): Phase 1/2 readout est. (NCT07591
 597)
DESCRIPTION:Fruzaqla / Elunate (Fruquintinib)\, phase 1/2\, Colorectal Canc
 er.\nStudy: A Multicenter\, Phase Ib/II Clinical Trial to Evaluate the Eff
 icacy and Safety of Concurrent Combination Therapy of S-531011 Plus Fruqui
 ntinib or S-531011 Plus Fruquintinib Plus Pembrolizumab in Patients With M
 SS/pMMR Colorectal Cancer\nEstimated primary completion: July 2027. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/fruquintinib#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT07591597
URL:https://assetmemo.bio/drug/fruquintinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07051785-2237@assetmemo.bio
DTSTAMP:20261121T004030Z
DTSTART;VALUE=DATE:20270706
DTEND;VALUE=DATE:20270707
SUMMARY:Fruzaqla / Elunate (Fruquintinib): Phase 2 readout est. (NCT0705178
 5)
DESCRIPTION:Fruzaqla / Elunate (Fruquintinib)\, phase 2\, Colorectal Cancer
 .\nStudy: Fruquintinib vs Bevacizumab Combined With Irinotecan Liposome an
 d Capecitabine as Second-Line Therapy for Advanced Metastatic Colorectal C
 ancer\nEstimated primary completion: 6 July 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/fruquintinib#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07051785
URL:https://assetmemo.bio/drug/fruquintinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07515820-2237@assetmemo.bio
DTSTAMP:20261121T004030Z
DTSTART;VALUE=DATE:20270728
DTEND;VALUE=DATE:20270729
SUMMARY:Fruzaqla / Elunate (Fruquintinib): Phase 2 readout est. (NCT0751582
 0)
DESCRIPTION:Fruzaqla / Elunate (Fruquintinib)\, phase 2\, Colorectal Cancer
 .\nStudy: SHR-3821 in Advanced Colorectal Cancer: an Exploratory Study\nEs
 timated primary completion: 28 July 2027. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/fruquintinib#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT07515820
URL:https://assetmemo.bio/drug/fruquintinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07483684-2237@assetmemo.bio
DTSTAMP:20261121T004030Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Fruzaqla / Elunate (Fruquintinib): Phase 3 readout est. (NCT0748368
 4)
DESCRIPTION:Fruzaqla / Elunate (Fruquintinib)\, phase 3\, Colorectal Cancer
 .\nStudy: A Clinical Study to Evaluate Injection TQB2102 for the Treatment
  of Patients With HER2 IHC3+ Advanced Colorectal Cancer Who Progressed Aft
 er Treatment With Oxaliplatin\, Irinotecan and Fluoropyrimidine-Based Drug
 s\nEstimated primary completion: August 2027. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/fruquintinib#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07483684
URL:https://assetmemo.bio/drug/fruquintinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07353268-2237@assetmemo.bio
DTSTAMP:20261121T004030Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Fruzaqla / Elunate (Fruquintinib): Phase 2 readout est. (NCT0735326
 8)
DESCRIPTION:Fruzaqla / Elunate (Fruquintinib)\, phase 2\, Colorectal Cancer
 .\nStudy: Phase Ib/II Study of QL1706 + Fruquintinib + SCRT vs. Standard T
 hird-Line Therapy in Unresectable Liver-Metastatic pMMR/MSS Colorectal Can
 cer: Safety\, Tolerability\, and Efficacy.\nEstimated primary completion: 
 31 August 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/fruqu
 intinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07353268
URL:https://assetmemo.bio/drug/fruquintinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07689292-2237@assetmemo.bio
DTSTAMP:20261121T004030Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Fruzaqla / Elunate (Fruquintinib): Phase 2 readout est. (NCT0768929
 2)
DESCRIPTION:Fruzaqla / Elunate (Fruquintinib)\, phase 2.\nStudy: Sac-TMT Co
 mbined With Fruquintinib as Second-Line Treatment in Patients With Advance
 d Gastric/Gastroesophageal Junction Adenocarcinoma\nEstimated primary comp
 letion: 31 August 2027. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/fruquintinib#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07689292
URL:https://assetmemo.bio/drug/fruquintinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07888309-2237@assetmemo.bio
DTSTAMP:20261121T004030Z
DTSTART;VALUE=DATE:20270911
DTEND;VALUE=DATE:20270912
SUMMARY:Fruzaqla / Elunate (Fruquintinib): Phase 2 readout est. (NCT0788830
 9)
DESCRIPTION:Fruzaqla / Elunate (Fruquintinib)\, phase 2.\nStudy: SCRT + Fru
 quintinib + Tislelizumab + CAPOX Versus SCRT + Tislelizumab + CAPOX as Neo
 adjuvant Therapy for Locally Advanced Low Rectal Cancer\nEstimated primary
  completion: 11 September 2027. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/fruquintinib#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07888309
URL:https://assetmemo.bio/drug/fruquintinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06562543-2237@assetmemo.bio
DTSTAMP:20261121T004030Z
DTSTART;VALUE=DATE:20271004
DTEND;VALUE=DATE:20271005
SUMMARY:Fruzaqla / Elunate (Fruquintinib): Phase 4 readout est. (NCT0656254
 3)
DESCRIPTION:Fruzaqla / Elunate (Fruquintinib)\, phase 4\, Colorectal Cancer
 .\nStudy: A Trial to Evaluate the Safety and Activity of Fruquintinib in M
 inority Populations With Advanced\, Previously Treated Colorectal Cancer\n
 Estimated primary completion: 4 October 2027. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/fruquintinib#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT06562543
URL:https://assetmemo.bio/drug/fruquintinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07170982-2237@assetmemo.bio
DTSTAMP:20261121T004030Z
DTSTART;VALUE=DATE:20271015
DTEND;VALUE=DATE:20271016
SUMMARY:Fruzaqla / Elunate (Fruquintinib): Phase 2 readout est. (NCT0717098
 2)
DESCRIPTION:Fruzaqla / Elunate (Fruquintinib)\, phase 2\, Endometrial Cance
 r.\nStudy: Fruquintinib Combined With Standard Chemotherapy Versus Standar
 d Chemotherapy as First-line Treatment for Advanced pMMR Endometrial Cance
 r\nEstimated primary completion: 15 October 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/fruquintinib#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07170982
URL:https://assetmemo.bio/drug/fruquintinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05831891-2237@assetmemo.bio
DTSTAMP:20261121T004030Z
DTSTART;VALUE=DATE:20271022
DTEND;VALUE=DATE:20271023
SUMMARY:Fruzaqla / Elunate (Fruquintinib): Phase 2 readout est. (NCT0583189
 1)
DESCRIPTION:Fruzaqla / Elunate (Fruquintinib)\, phase 2\, Renal Cell Carcin
 oma.\nStudy: Fruquintinib Plus Serplulimab as First-Line Therapy for Metas
 tatic Non-Clear Cell Renal Cell Carcinoma\nEstimated primary completion: 2
 2 October 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/fruqu
 intinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT05831891
URL:https://assetmemo.bio/drug/fruquintinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07261709-2237@assetmemo.bio
DTSTAMP:20261121T004030Z
DTSTART;VALUE=DATE:20271030
DTEND;VALUE=DATE:20271031
SUMMARY:Fruzaqla / Elunate (Fruquintinib): Phase 2 readout est. (NCT0726170
 9)
DESCRIPTION:Fruzaqla / Elunate (Fruquintinib)\, phase 2\, Colorectal Cancer
 .\nStudy: Trifluridine/Tipiracil Plus Fruquintinib vs. Trifluridine/Tipira
 cil Plus Bevacizumab in Refractory Metastatic Colorectal Cancer: A Randomi
 zed\, Controlled\, Open-Label\, Non-Inferiority Trial\nEstimated primary c
 ompletion: 30 October 2027. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/fruquintinib#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT07261709
URL:https://assetmemo.bio/drug/fruquintinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07621159-2237@assetmemo.bio
DTSTAMP:20261121T004030Z
DTSTART;VALUE=DATE:20271101
DTEND;VALUE=DATE:20271102
SUMMARY:Fruzaqla / Elunate (Fruquintinib): Phase 1/2 readout est. (NCT07621
 159)
DESCRIPTION:Fruzaqla / Elunate (Fruquintinib)\, phase 1/2\, Colorectal Canc
 er.\nStudy: A Phase Ib/II Study of HDM2017 in Combination With Standard of
  Care in Advanced Colorectal Cancer\nEstimated primary completion: 1 Novem
 ber 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/fruquintini
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 621159
URL:https://assetmemo.bio/drug/fruquintinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07392346-2237@assetmemo.bio
DTSTAMP:20261121T004030Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Fruzaqla / Elunate (Fruquintinib): Phase 2 readout est. (NCT0739234
 6)
DESCRIPTION:Fruzaqla / Elunate (Fruquintinib)\, phase 2.\nStudy: Safety and
  Efficacy of Fruquintinib Plus Nab-Paclitaxel and Iparomlimab and Tuvonral
 imab Injection in the Second-Line Treatment for Immunotherapy-experienced 
 Advanced Gastric Cancer\nEstimated primary completion: 30 November 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/fruquintinib#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT07392346
URL:https://assetmemo.bio/drug/fruquintinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07384377-2237@assetmemo.bio
DTSTAMP:20261121T004030Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Fruzaqla / Elunate (Fruquintinib): Phase 3 readout est. (NCT0738437
 7)
DESCRIPTION:Fruzaqla / Elunate (Fruquintinib)\, phase 3\, Colorectal Cancer
 .\nStudy: JSKN003 Versus Physician Choiced Treatment in Patients With HER2
 -positive and Advanced Colorectal Cancer Who Had Failed to Respond to Oxal
 iplatin\, 5-Fu\, and Irinotecan\nEstimated primary completion: 30 November
  2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/fruquintinib#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07384
 377
URL:https://assetmemo.bio/drug/fruquintinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07136077-2237@assetmemo.bio
DTSTAMP:20261121T004030Z
DTSTART;VALUE=DATE:20271201
DTEND;VALUE=DATE:20271202
SUMMARY:Fruzaqla / Elunate (Fruquintinib): Phase 2 readout est. (NCT0713607
 7)
DESCRIPTION:Fruzaqla / Elunate (Fruquintinib)\, phase 2\, Colorectal Cancer
 .\nStudy: A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-define
 d Minimal Residual Disease in Colorectal Cancer After Completion of Adjuva
 nt Chemotherapy\nEstimated primary completion: 1 December 2027. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/fruquintinib#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07136077
URL:https://assetmemo.bio/drug/fruquintinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07622550-2237@assetmemo.bio
DTSTAMP:20261121T004030Z
DTSTART;VALUE=DATE:20271215
DTEND;VALUE=DATE:20271216
SUMMARY:Fruzaqla / Elunate (Fruquintinib): Phase 2 readout est. (NCT0762255
 0)
DESCRIPTION:Fruzaqla / Elunate (Fruquintinib)\, phase 2\, Colorectal Cancer
 .\nStudy: A Single-arm\, Multicenter Clinical Study of Fruquintinib Combin
 ed With Serplulimab and Chemotherapy as First-line Treatment for Patients 
 With RAS/BRAF-mutated Advanced Colorectal Cance\nEstimated primary complet
 ion: 15 December 2027. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/fruquintinib#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07622550
URL:https://assetmemo.bio/drug/fruquintinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07896096-2237@assetmemo.bio
DTSTAMP:20261121T004030Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Fruzaqla / Elunate (Fruquintinib): Phase 2 readout est. (NCT0789609
 6)
DESCRIPTION:Fruzaqla / Elunate (Fruquintinib)\, phase 2\, Colorectal Cancer
 .\nStudy: Ivarmacitinib Combined With Camrelizumab and Fruquintinib for Pa
 tients With Metastatic Colorectal Cancer After Failure of Second-line or L
 ater Treatment\nEstimated primary completion: 30 December 2027. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/fruquintinib#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07896096
URL:https://assetmemo.bio/drug/fruquintinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07552402-2237@assetmemo.bio
DTSTAMP:20261121T004030Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Fruzaqla / Elunate (Fruquintinib): Phase na readout est. (NCT075524
 02)
DESCRIPTION:Fruzaqla / Elunate (Fruquintinib)\, phase na.\nStudy: Oral Pacl
 itaxel Plus Fruquintinib Verus Investigator's Choice in Second-Line Advanc
 ed Gastric Cancer\nEstimated primary completion: 30 December 2027. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/fruquintinib#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT07552402
URL:https://assetmemo.bio/drug/fruquintinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07488533-2237@assetmemo.bio
DTSTAMP:20261121T004030Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Fruzaqla / Elunate (Fruquintinib): Phase 2 readout est. (NCT0748853
 3)
DESCRIPTION:Fruzaqla / Elunate (Fruquintinib)\, phase 2\, Renal Cell Carcin
 oma.\nStudy: Comparing the Combination of Sullumab and Fruquintinib in Pos
 toperative Adjuvant Therapy for High Recurrence Risk Non Transparent Renal
  Cell Carcinoma\nEstimated primary completion: 31 December 2027. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/fruquintinib#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT07488533
URL:https://assetmemo.bio/drug/fruquintinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06992258-2237@assetmemo.bio
DTSTAMP:20261121T004030Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Fruzaqla / Elunate (Fruquintinib): Phase 2 readout est. (NCT0699225
 8)
DESCRIPTION:Fruzaqla / Elunate (Fruquintinib)\, phase 2\, Colorectal Cancer
 .\nStudy: A Randomized Phase 2 Trial of Fruquintinib and TAS-102 as Compar
 ed to Fruquintinib in Patients With Refractory Advanced/Metastatic Colorec
 tal Cancer\nEstimated primary completion: 31 December 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/fruquintinib#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT06992258
URL:https://assetmemo.bio/drug/fruquintinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07150403-2237@assetmemo.bio
DTSTAMP:20261121T004030Z
DTSTART;VALUE=DATE:20280228
DTEND;VALUE=DATE:20280229
SUMMARY:Fruzaqla / Elunate (Fruquintinib): Phase 2 readout est. (NCT0715040
 3)
DESCRIPTION:Fruzaqla / Elunate (Fruquintinib)\, phase 2\, Colorectal Cancer
 .\nStudy: Second-line Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Fruqui
 ntinib Versus Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Bevacizumab in
  Metastatic Colorectal Cancer\nEstimated primary completion: 28 February 2
 028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/fruquintinib#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0715040
 3
URL:https://assetmemo.bio/drug/fruquintinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06871527-2237@assetmemo.bio
DTSTAMP:20261121T004030Z
DTSTART;VALUE=DATE:20280330
DTEND;VALUE=DATE:20280331
SUMMARY:Fruzaqla / Elunate (Fruquintinib): Phase 1/2 readout est. (NCT06871
 527)
DESCRIPTION:Fruzaqla / Elunate (Fruquintinib)\, phase 1/2.\nStudy: Fruquint
 inib Combined With PD-1 Inhibitor and FOLFOX as First-Line Treatment For A
 dvanced Gastric Cancer\nEstimated primary completion: 30 March 2028. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/fruquintinib#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT06871527
URL:https://assetmemo.bio/drug/fruquintinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06888037-2237@assetmemo.bio
DTSTAMP:20261121T004030Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Fruzaqla / Elunate (Fruquintinib): Phase 2 readout est. (NCT0688803
 7)
DESCRIPTION:Fruzaqla / Elunate (Fruquintinib)\, phase 2.\nStudy: Fruquintin
 ib Combined With PD-1 Inhibitor as First-line Maintenance Therapy for Adva
 nced Gastric Cancer\nEstimated primary completion: 31 March 2028. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/fruquintinib#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT06888037
URL:https://assetmemo.bio/drug/fruquintinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07130903-2237@assetmemo.bio
DTSTAMP:20261121T004030Z
DTSTART;VALUE=DATE:20280417
DTEND;VALUE=DATE:20280418
SUMMARY:Fruzaqla / Elunate (Fruquintinib): Phase 2 readout est. (NCT0713090
 3)
DESCRIPTION:Fruzaqla / Elunate (Fruquintinib)\, phase 2\, Colorectal Cancer
 .\nStudy: Amplitude-Modulated Radiofrequency Electromagnetic Fields (AM RF
  EMF) in Combination With Fruquintinib in Refractory Metastatic Colorectal
  Cancer\nEstimated primary completion: 17 April 2028. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/fruquintinib#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT07130903
URL:https://assetmemo.bio/drug/fruquintinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06985316-2237@assetmemo.bio
DTSTAMP:20261121T004030Z
DTSTART;VALUE=DATE:20280427
DTEND;VALUE=DATE:20280428
SUMMARY:Fruzaqla / Elunate (Fruquintinib): Phase na readout est. (NCT069853
 16)
DESCRIPTION:Fruzaqla / Elunate (Fruquintinib)\, phase na\, Colorectal Cance
 r.\nStudy: An Exploratory Clinical Study Evaluating the Efficacy and Safet
 y of Tunlametinib Combined With Fruquintinib in the Third-line Treatment o
 f Advanced Colorectal Cancer Patients With RAS Mutations.\nEstimated prima
 ry completion: 27 April 2028. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/fruquintinib#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT06985316
URL:https://assetmemo.bio/drug/fruquintinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07724223-2237@assetmemo.bio
DTSTAMP:20261121T004030Z
DTSTART;VALUE=DATE:20281001
DTEND;VALUE=DATE:20281002
SUMMARY:Fruzaqla / Elunate (Fruquintinib): Phase 2 readout est. (NCT0772422
 3)
DESCRIPTION:Fruzaqla / Elunate (Fruquintinib)\, phase 2\, Colorectal Cancer
 .\nStudy: Fruquintinib Plus Anti-EGFR Antibody for Third-Line Treatment of
  RAS Wild-Type mCRC\nEstimated primary completion: 1 October 2028. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/fruquintinib#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT07724223
URL:https://assetmemo.bio/drug/fruquintinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07819019-2237@assetmemo.bio
DTSTAMP:20261121T004030Z
DTSTART;VALUE=DATE:20281001
DTEND;VALUE=DATE:20281002
SUMMARY:Fruzaqla / Elunate (Fruquintinib): Phase 2 readout est. (NCT0781901
 9)
DESCRIPTION:Fruzaqla / Elunate (Fruquintinib)\, phase 2.\nStudy: A Phase II
  Study of Irinotecan Liposome Plus Fruquintinib and Sintilimab in Second-L
 ine PD-L1-Positive Advanced Gastric Cancer\nEstimated primary completion: 
 1 October 2028. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/fruqu
 intinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07819019
URL:https://assetmemo.bio/drug/fruquintinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07904130-2237@assetmemo.bio
DTSTAMP:20261121T004030Z
DTSTART;VALUE=DATE:20281001
DTEND;VALUE=DATE:20281002
SUMMARY:Fruzaqla / Elunate (Fruquintinib): Phase 2 readout est. (NCT0790413
 0)
DESCRIPTION:Fruzaqla / Elunate (Fruquintinib)\, phase 2\, Colorectal Cancer
 .\nStudy: Personalized Ultrafractionated Stereotactic Adaptive Radiotherap
 y Combined With Penpulimab and Fruquintinib for Advanced Colorectal Cancer
 \nEstimated primary completion: 1 October 2028. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/fruquintinib#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT07904130
URL:https://assetmemo.bio/drug/fruquintinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07042685-2237@assetmemo.bio
DTSTAMP:20261121T004030Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Fruzaqla / Elunate (Fruquintinib): Phase 2 readout est. (NCT0704268
 5)
DESCRIPTION:Fruzaqla / Elunate (Fruquintinib)\, phase 2\, Colorectal Cancer
 .\nStudy: Trial of 5-Fluorouracil (5FU)-Based Therapy in Combination With 
 Fruquintinib in Patients With Locally Advanced Unresectable or Metastatic 
 Colorectal Cancer\nEstimated primary completion: December 2028. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/fruquintinib#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07042685
URL:https://assetmemo.bio/drug/fruquintinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06980532-2237@assetmemo.bio
DTSTAMP:20261121T004030Z
DTSTART;VALUE=DATE:20281230
DTEND;VALUE=DATE:20281231
SUMMARY:Fruzaqla / Elunate (Fruquintinib): Phase 1/2 readout est. (NCT06980
 532)
DESCRIPTION:Fruzaqla / Elunate (Fruquintinib)\, phase 1/2\, Colorectal Canc
 er.\nStudy: Glumetinib Combined With Fruquintinib in the Treatment of MET 
 Amplification or Protein Overexpression in Third-Line Unresectable Metasta
 tic Colorectal Cancer\nEstimated primary completion: 30 December 2028. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/fruquintinib#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT06980532
URL:https://assetmemo.bio/drug/fruquintinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07362836-2237@assetmemo.bio
DTSTAMP:20261121T004030Z
DTSTART;VALUE=DATE:20281230
DTEND;VALUE=DATE:20281231
SUMMARY:Fruzaqla / Elunate (Fruquintinib): Phase 3 readout est. (NCT0736283
 6)
DESCRIPTION:Fruzaqla / Elunate (Fruquintinib)\, phase 3\, Colorectal Cancer
 .\nStudy: Fruquintinib Versus Bevacizumab Plus Chemotherapy in Second-Line
  RAS-Mutant Metastatic Colorectal Cancer (FRU-RAS)\nEstimated primary comp
 letion: 30 December 2028. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/fruquintinib#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT07362836
URL:https://assetmemo.bio/drug/fruquintinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06584032-2237@assetmemo.bio
DTSTAMP:20261121T004030Z
DTSTART;VALUE=DATE:20290108
DTEND;VALUE=DATE:20290109
SUMMARY:Fruzaqla / Elunate (Fruquintinib): Phase 3 readout est. (NCT0658403
 2)
DESCRIPTION:Fruzaqla / Elunate (Fruquintinib)\, phase 3\, Endometrial Cance
 r.\nStudy: Study of Fruquintinib Plus Sintilimab for Treatment of Advanced
  Endometrial Cancer\nEstimated primary completion: 8 January 2029. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/fruquintinib#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT06584032
URL:https://assetmemo.bio/drug/fruquintinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07885384-2237@assetmemo.bio
DTSTAMP:20261121T004030Z
DTSTART;VALUE=DATE:20290428
DTEND;VALUE=DATE:20290429
SUMMARY:Fruzaqla / Elunate (Fruquintinib): Phase 3 readout est. (NCT0788538
 4)
DESCRIPTION:Fruzaqla / Elunate (Fruquintinib)\, phase 3\, Colorectal Cancer
 .\nStudy: Fruquintinib Combined With Capecitabine as Adjuvant Extended The
 rapy After R0 Resection and Perioperative Chemotherapy in Patients With Li
 ver-Only Metastatic Colorectal Cancer\nEstimated primary completion: 28 Ap
 ril 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/fruquintini
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 885384
URL:https://assetmemo.bio/drug/fruquintinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06856837-2237@assetmemo.bio
DTSTAMP:20261121T004030Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Fruzaqla / Elunate (Fruquintinib): Phase 2 readout est. (NCT0685683
 7)
DESCRIPTION:Fruzaqla / Elunate (Fruquintinib)\, phase 2\, Colorectal Cancer
 .\nStudy: - IKF/AIO-QUINTIS - Evaluating Fruquintinib in Combination With 
 Tislelizumab in Microsatellite Stable / Proficient Mismatch Repair (MSS/pM
 MR) Metastatic Colorectal Cancer Without Active Liver Metastases\nEstimate
 d primary completion: 31 December 2029. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/fruquintinib#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT06856837
URL:https://assetmemo.bio/drug/fruquintinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07286695-2237@assetmemo.bio
DTSTAMP:20261121T004030Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Fruzaqla / Elunate (Fruquintinib): Phase 2 readout est. (NCT0728669
 5)
DESCRIPTION:Fruzaqla / Elunate (Fruquintinib)\, phase 2\, Colorectal Cancer
 .\nStudy: Fruquintinib Combined With Trifluridine/Tipiracil Versus Bevaciz
 umab Combined With Trifluridine/Tipiracil for Advanced Metastatic Colorect
 al Cancer\nEstimated primary completion: 31 December 2029. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/fruquintinib#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT07286695
URL:https://assetmemo.bio/drug/fruquintinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07791758-2237@assetmemo.bio
DTSTAMP:20261121T004030Z
DTSTART;VALUE=DATE:20300904
DTEND;VALUE=DATE:20300905
SUMMARY:Fruzaqla / Elunate (Fruquintinib): Phase 1/2 readout est. (NCT07791
 758)
DESCRIPTION:Fruzaqla / Elunate (Fruquintinib)\, phase 1/2.\nStudy: A Clinic
 al Trial of LBL-024 Combination Drug in Patients With Metastatic Colorecta
 l Carcinoma\nEstimated primary completion: 4 September 2030. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/fruquintinib#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT07791758
URL:https://assetmemo.bio/drug/fruquintinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07270991-2237@assetmemo.bio
DTSTAMP:20261121T004030Z
DTSTART;VALUE=DATE:20301130
DTEND;VALUE=DATE:20301201
SUMMARY:Fruzaqla / Elunate (Fruquintinib): Phase 3 readout est. (NCT0727099
 1)
DESCRIPTION:Fruzaqla / Elunate (Fruquintinib)\, phase 3.\nStudy: Trifluridi
 ne/Tipiracil + Fruquintinib Versus Trifluridine/Tipiracil Alone for Metast
 atic Oeso-gastric Adenocarcinoma\nEstimated primary completion: 30 Novembe
 r 2030. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/fruquintinib#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0727
 0991
URL:https://assetmemo.bio/drug/fruquintinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07904156-2237@assetmemo.bio
DTSTAMP:20261121T004030Z
DTSTART;VALUE=DATE:20301230
DTEND;VALUE=DATE:20301231
SUMMARY:Fruzaqla / Elunate (Fruquintinib): Phase 3 readout est. (NCT0790415
 6)
DESCRIPTION:Fruzaqla / Elunate (Fruquintinib)\, phase 3\, Renal Cell Carcin
 oma.\nStudy: A Phase III Randomized Controlled Trial of Serplulimab Plus F
 ruquintinib as Adjuvant Therapy for High-Risk Non-Clear Cell Renal Cell Ca
 rcinoma\nEstimated primary completion: 30 December 2030. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/fruquintinib#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT07904156
URL:https://assetmemo.bio/drug/fruquintinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07124858-2237@assetmemo.bio
DTSTAMP:20261121T004030Z
DTSTART;VALUE=DATE:20310301
DTEND;VALUE=DATE:20310302
SUMMARY:Fruzaqla / Elunate (Fruquintinib): Phase na readout est. (NCT071248
 58)
DESCRIPTION:Fruzaqla / Elunate (Fruquintinib)\, phase na\, Colorectal Cance
 r.\nStudy: Prospective National Cohort Evaluating Prognostic Factors for E
 fficacy of Fruquintinib Treatment in Patients With Metastatic Colorectal C
 ancer\nEstimated primary completion: 1 March 2031. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/fruquintinib#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT07124858
URL:https://assetmemo.bio/drug/fruquintinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
